Cargando…
Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitors—Comparison Against a Therapy Naïve Cohort
With recent studies uncovering the complex landscape of immune checkpoint regulators in gastric cancer (GC), we aimed to characterize the expression of the checkpoint proteins V-domain Ig suppressor of T-cell activation (VISTA), programmed cell death 1 ligand 1 (PD-L1), and programmed cell death pro...
Autores principales: | Schoop, Hauke, Bregenzer, Anna, Halske, Christine, Behrens, Hans-Michael, Krüger, Sandra, Egberts, Jan-Hendrik, Röcken, Christoph |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931207/ https://www.ncbi.nlm.nih.gov/pubmed/31865179 http://dx.doi.org/10.1016/j.tranon.2019.11.004 |
Ejemplares similares
-
Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy Response
por: Freiin Grote, Antonia, et al.
Publicado: (2019) -
The putative pleiotropic functions of meprin β in gastric cancer
por: Siemsen, Wiebke, et al.
Publicado: (2023) -
Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy
por: Paszt, Attila, et al.
Publicado: (2023) -
Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
por: Dottermusch, Matthias, et al.
Publicado: (2019) -
Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine
por: Röcken, Christoph, et al.
Publicado: (2021)